NCT06405321 2026-01-14
Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
Guangxi Medical University
Recruiting
Clinical Trials
13 trialsNCT04727307 2025-09-30
AB-LATE02
University Hospital, Montpellier
Phase 2 Recruiting
NCT06045975 2025-04-02
DUMELEP
Assistance Publique - Hôpitaux de Paris
Phase 2 Recruiting
NCT05137899 2025-03-11
ADVANCE HCC
Ontario Clinical Oncology Group (OCOG)
Phase 2 Terminated
NCT06261138 2024-02-15
Survival Analysis: TACE vs. Combination Therapy in HCC
Zhejiang University
Completed
NCT06003673 2023-10-24
A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC
First Affiliated Hospital of Fujian Medical University
Phase 4 Unknown
NCT04135690 2023-08-15
HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial
Sun Yat-sen University
Phase 2 Unknown
NCT04170179 2021-02-23
Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis
Sun Yat-sen University
Phase 2 Unknown
NCT04025437 2019-09-04
Neoadjuvant Radiotherapy for HCC Involving Type I PVTT
Guangxi Medical University
Phase 2/3 Unknown
NCT02584556 2019-06-04
Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma
Guangxi Medical University
Phase 2/3 Withdrawn
NCT00276705 2013-09-17
Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00471484 2011-06-22
Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01182272 2010-08-16
Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Unknown